Exhibit 99.1
Acura Pharmaceuticals Announces
Third Quarter 2021 Financial Results
Palatine, IL – (November 15, 2021) - Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021.
The Company reported revenues of $270 thousand, an operating loss of $531 thousand and a net loss of $262 thousand or $0.00 per diluted share for the third quarter 2021 compared to revenues of $410 thousand, an operating loss of $565 thousand and a net loss of $678 thousand or $0.02 per diluted share for the same period in 2020.
For the nine months ended September 30, 2021, the Company reported revenues of $1.5 million, an operating loss of $977 thousand and a net loss of $908 thousand or $0.02 per diluted share compared to revenues of $2.9 million, an operating loss of $627 thousand and a net loss of $965 thousand or $0.03 per diluted share for the same period in 2020.
The three and nine month 2021 results were positively affected by the SBA forgiveness in July of our 1st Loan under the Paycheck Protection Program of $269 thousand.
Revenue for the third quarter 2021 and 2020 included $200 thousand and $300 thousand, respectively, in license fees derived from the license agreement with Abuse Deterrent Pharma, LLC (“AD Pharma”) that was amended in July 2021. The Company also recorded royalty revenue of $67 thousand and $14 thousand, respectively, for the third quarter 2021 and 2020. Revenue for the nine month period ended September 30, 2021 and 2020 included $1.4 million and $2.4 million, respectively, in license fees derived from the license agreement with AD Pharma. The Company also recorded royalty revenue of $102 thousand and $81 thousand, respectively, for the nine month periods ended September 30, 2021 and 2020.
Research and development expense was $385 thousand for the third quarter 2021, compared to $519 thousand for the same period in 2020. Research and development expense was $1.2 million and $1.4 million for each of the nine month periods ended September 30, 2021 and 2020, respectively. The expenses reported for these periods were for our research facility, primarily associated with development of LTX-03.
General and administrative expense was $416 thousand for the third quarter 2021, versus $456 thousand for the same period in 2020. General and administrative expense was $1.3 million for the nine month period ended September 30, 2021, versus $2.1 million for the same period in 2020. Included in the expense for 2020 was a one-time $668 thousand charge for an impairment of an intangible asset.
In October 2021, we were notified by our bank that our 2nd Loan under the Paycheck Protection Program of $266 thousand has been forgiven in its entirety. This amount will be reflected in our 4th quarter and full year 2021 results. With this notification, all loans under the Paycheck Protection Program have been forgiven in their entirety.
As of November 12, 2021, the Company had a cash balance of approximately $130 thousand.
In June 2019, we entered into License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC, which was amended in October 2020 and July 2021 (“AD Pharma Amended Agreement”). The AD Pharma Amended Agreement grants AD Pharma exclusive commercialization rights for our lead product candidate, LTX-03 (hydrocodone bitartrate with acetaminophen immediate-release tablets utilizing Acura’s patented LIMITx™ technology) as well as to LTX-02 (oxycodone/acetaminophen) and LTX-09 (alprazolam). The AD Pharma Amended Agreement required AD Pharma to pay us a monthly license payment of $350,000 for a period from inception up to April 2020 at which time the payment became $200,000 per month and ended on July 31, 2021, and to reimburse us all our outside development costs for LTX-03. Upon commercialization of LTX-03, Acura will be entitled to stepped royalties on sales and is eligible for certain sales related milestones. However, if the NDA application for LTX-03 is not accepted by the FDA by February 28, 2022, AD Pharma has the option of terminating the Agreement and taking ownership of the intellectual property.
The AD Pharma Amended Agreement is more fully described in our press releases dated July 2, 2020, October 28, 2020, and July 26, 2021 as well as in our Form 8-Ks filed July 5, 2020, October 29, 2020, and July 28, 2021 and our Form 10-Ks filed March 31, 2020 and March 31, 2021.
About Acura Pharmaceuticals
Acura Pharmaceuticals is an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products: LIMITx™ Technology, AVERSION® Technology and IMPEDE® Technology.
LIMITxTM Technology a development stage technology, is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested by neutralizing stomach acid with buffer ingredients but deliver efficacious amounts of drug when taken as a single tablet with a nominal buffer dose. In June 20190, we entered into License, Development and Commercialization Agreement, which was amended in October 2020, with Abuse Deterrent Pharma, LLC, a Kentucky limited liability company and a special purpose company representing a consortium of investors for the development of LTX-03. AD Pharma has exclusive commercialization rights in the United States to LTX-03 as well as to LTX-02 (oxycodone/acetaminophen) and LTX-09 (alprazolam).
AVERSION® Technology, used in the FDA approved drug OXAYDO® (oxycodone HCl) marketed by Assertio Holdings Inc., utilizes polymers designed to limit the abuse of the product by nasal snorting and injection. AVERSION® Technology is also licensed to KemPharm for use in certain of their products.
IMPEDE® Technology, used in NEXAFED® (pseudoephedrine HCl) and NEXAFED® Sinus (pseudoephedrine HCl/acetaminophen) marketed by MainPointe Pharmaceuticals, utilizes polymers and other ingredients to disrupt the extraction and processing of pseudoephedrine from the tablets into methamphetamine.
Forward-looking Statements:
Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to:
| • | our ability to fund or obtain funding for our continuing operations, including the development of our products utilizing our LIMITx and IMPEDE technologies; |
| • | whether we will receive FDA acceptance for an NDA for LTX-03 by the target date; |
| • | whether our licensees will terminate the license prior to commercialization; |
| • | the expected results of clinical studies relating to LTX-03 or any successor product candidate, the date by which such studies will complete and the results will be available and whether any product candidate will ultimately receive FDA approval; |
| • | the ability of LTX-03 single tablets to achieve bioequivalence or to demonstrate efficacy in a clinical study; |
| • | whether our licensing partners will develop any additional products and utilize Acura for such development; |
| • | whether LIMITx will retard the release of opioid active ingredients as dose levels increase; |
| • | whether the extent to which products formulated with the LIMITx technology mitigate respiratory depression risk will be determined sufficient by the FDA; |
| • | our and our licensee’s ability to successfully launch and commercialize our products and technologies; |
| • | our and our licensee’s ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies; |
| • | the market acceptance of, timing of commercial launch and competitive environment for any of our products; |
| • | our ability to develop and enter into additional license agreements for our product candidates using our technologies; |
| • | the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties; |
| • | the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation; |
| • | the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support an NDA and FDA approval of our product candidates; |
| • | changes in regulatory requirements; |
| • | adverse safety findings relating to our commercialized products or product candidates in development; |
| • | whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and whether we will be able to promote the features of our technologies; and |
| • | whether our product candidates will ultimately perform as intended in commercial settings. |
In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “indicate,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “seek”, “should,” “suggest,” “target,” “will,” “would” and similar expressions that convey the uncertainty of future events or outcomes are used to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Acura. Given these uncertainties, you should not place undue reliance on these forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission. While Acura may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law.
Contact:
Acura
Investor Relations
investors@acurapharm.com
847-705-7709
ACURA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
| (unaudited) | (audited) | |||||||
| September 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Assets – current | $ | 845 | $ | 1,179 | ||||
| Property, plant and equipment, net | 449 | 484 | ||||||
| Other assets | 112 | 73 | ||||||
| Total assets | $ | 1,406 | $ | 1,736 | ||||
| Other liabilities - current | $ | 980 | $ | 680 | ||||
| Loan under CARES Act - current | - | 164 | ||||||
| Accrued interest to related party – current | - | 678 | ||||||
| Convertible debt to related party – current | - | 6,000 | ||||||
| Other liabilities – non current | 25 | - | ||||||
| Loan under CARES Act – non current | 266 | 105 | ||||||
| Stockholders' equity (deficit) | 135 | (5,891 | ) | |||||
| Total liabilities and stockholders' equity (deficit) | $ | 1,406 | $ | 1,736 | ||||
ACURA PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(in thousands, except per share amounts)
| Three months Ended September 30, | Nine months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenues: | ||||||||||||||||
| Royalties | $ | 67 | $ | 14 | $ | 102 | $ | 81 | ||||||||
| Collaboration- related party | 3 | 96 | 25 | 148 | ||||||||||||
| License fees – related party | 200 | 300 | 1,400 | 2,400 | ||||||||||||
| Product sales, net of allowance (Note 3) | - | - | - | 223 | ||||||||||||
| Total revenues | 270 | 410 | 1,527 | 2,852 | ||||||||||||
| Expenses: | ||||||||||||||||
| Research and development | 385 | 519 | 1,180 | 1,351 | ||||||||||||
| General and administrative | 416 | 456 | 1,324 | 2,128 | ||||||||||||
| Total expenses | 801 | 975 | 2,504 | 3,479 | ||||||||||||
| Operating loss | (531 | ) | (565 | ) | (977 | ) | (627 | ) | ||||||||
| Gain on forgiveness of a loan under CARES Act (Note 7) | 269 | - | 269 | - | ||||||||||||
| Interest expense – related party (Note 9) | - | (113 | ) | (200 | ) | (338 | ) | |||||||||
| Loss before provision for income taxes | (262 | ) | (678 | ) | (908 | ) | (965 | ) | ||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | $ | (262 | ) | $ | (678 | ) | $ | (908 | ) | $ | (965 | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic | $ | (0.00 | ) | $ | (0.02 | ) | $ | (0.02 | ) | $ | (0.03 | ) | ||||
| Diluted | $ | (0.00 | ) | $ | (0.02 | ) | $ | (0.02 | ) | $ | (0.03 | ) | ||||
| Weighted average number of shares outstanding: | ||||||||||||||||
| Basic | 75,561 | 32,336 | 50,464 | 32,304 | ||||||||||||
| Diluted | 75,561 | 32,336 | 50,464 | 32,304 | ||||||||||||